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Abstract: In the present study, 13 bromopyrrole alkaloids, including the oroidin analogs 
hymenidin (2), dispacamide B (3) and dispacamide D (4), stevensine (5) and spongiacidin 
B (6), their derivatives lacking the imidazole ring bromoaldisin (7), longamide B (8) and 
longamide A (9), the dimeric oroidin derivatives sceptrin (10) and dibromopalau’amine 
(11),  and  the  non-oroidin  bromopyrrolohomoarginin  (12),  manzacidin  A  (13),  and 
agelongine (14), obtained from marine sponges belonging to Axinella and Agelas genera 
have been screened in vitro against four parasitic protozoa, i.e., two Trypanosoma species 
(T. brucei rhodesiense and T. cruzi), Leishmania donovani and Plasmodium falciparum 
(K1  strain,  a  chloroquine  resistant  strain),  responsible  of  human  diseases  with  high 
morbidity and, in the case of malaria, high mortality. Our results indicate longamide B (8) 
and  dibromopalau’amine  (11)  to  be  promising  trypanocidal and  antileishmanial agents, 
while dispacamide B (3) and spongiacidin B (6) emerge as antimalarial lead compounds. In 
addition,  evaluation  of  the  activity  of  the  test  alkaloids  (2–14)  against  three  different 
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enzymes  (PfFabI,  PfFabG,  PfFabZ)  involved  in  the  de  novo  fatty  acid  biosynthesis 
pathway of P. falciparum (PfFAS-II) identified bromopyrrolohomoarginin (12) as a potent 
inhibitor of PfFabZ. The structural similarity within the series of tested molecules allowed 
us to draw some preliminary structure-activity relationships. Tests against the mammalian 
L6 cells revealed important clues on therapeutic index of the metabolites. This is the first 
detailed study on the antiprotozoal potential of marine bromopyrrole alkaloids. 
Keywords:  bromopyrrole  alkaloids;  antiprotozoal  activity;  enzyme  inhibition; 
Trypanosoma; Leishmania; Plasmodium 
 
1. Introduction 
Diseases  caused  by  single-celled  protozoal  parasites  affect  about  one  billion  people  with  a 
particular incidence in tropical countries. The major contribution to these dramatic numbers is given 
by malaria, caused by protozoa belonging to the genus Plasmodium (P. falciparum, P. ovale, P. vivax, 
P. malariae), with P. falciparum being responsible for most severe forms of the disease and most fatal 
cases. The improvement of hygienic conditions, the massive use of insecticides, and the discovery of 
different drugs played a great role in the nearly complete extinction of malaria in developed countries. 
Unfortunately, malaria is still a common cause of death (approximately one million per year) in the 
tropical countries of Africa, Asia and America, and tragically most of the victims are children under 
the age of five: every 30 seconds a child dies of malaria [1]. The increase in the number of fatal cases 
registered  in  recent  years  is  principally  due  to  the  spread  of  mosquitoes  resistant  to  common 
insecticides and, more importantly, the emergence of multi-drug resistant strains of Plasmodium. The 
latter  problem  makes  many  of  the  available  drugs  useless,  leaving  some  efficacy  only  to  the 
artemisinin-based therapies. Since malaria is a disease of worldwide implications and almost half of 
the world’s population is currently at risk for malaria infection, combating malaria is one of the highest 
priority programs of the WHO.  
The mortality of the remaining protozoal diseases is much less marked (nearly 100,000 deaths per 
year)  but  their  morbidity  is  also  extremely  high,  severely  affecting  the  quality of life of infected 
people. African trypanosomiasis (sleeping sickness) is caused by Trypanosoma brucei gambiense and 
T. brucei rhodesiense, which invade the central nervous system, leading to behavioural changes, coma, 
and  ultimately,  if  untreated,  death  [2].  Chagas'  disease  is  caused  by  T.  cruzi  with  the  vector 
contribution of a blood-sucking insect (triatome), which bites the victim and contaminates the wound 
with infected feces. The disease, which is also known as South American trypanosomiasis, is one of 
the  major  health  problems  in  Latin  America.  Leishmaniasis  is  caused  by  over  20  species  of 
intracellular parasites from the genus Leishmania, which are transmitted to humans by sand flies. This 
disease can give different clinical symptoms including cutaneous, mucosal, and visceral forms [3]. 
Both the cutaneous and mucosal forms can cause severe deformities to patients, including ulcerative 
skin  lesions  and  the  destruction  of  mucous  membranes,  in  some  cases  leading  to  permanent 
disfigurement. The visceral form of the disease, caused principally by L. donovani, L. infantum, and  Mar. Drugs 2010, 8                       
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L. chagasi, represents the greatest threat to human health, with symptoms ranging from fever and 
weight loss to hepatosplenomegaly, leading to death in untreated cases [4].  
The  chemotherapeutic  options  to  control  and  treat  these  protozoal  infections  are  dramatically 
limited to few classes of drugs which, in many cases, are associated with severe toxicity and variable 
efficacy.  The  unaffordable  cost  of  many  treatments  (e.g.,  amphotericin  B  is  very  effective  in 
leishmaniasis but it is too expensive) and the emerging resistance against these drugs make discovery 
and development of new, safe and effective antiprotozoal agents a pressing need. In this regard, marine 
organisms constitute an universally recognized source of potentially bioactive molecules, which have 
been enzymatically engineered and biologically validated. Marine invertebrates, such as sponges, have 
an  incredible  potential  to  produce  a  large  array  of  secondary  metabolites,  belonging  to  different 
structural  classes, often through the biosynthetic contribution  of microorganisms harbored in their 
tissues. In a recent review, we have collected the most promising classes of marine antimalarial lead 
compounds [5], while a number of other reviews can give an account of the activity of compounds 
originated from marine organisms against other protozoa [6].  
Bromopyrrole  alkaloids  are  a  well  known  class  of  sponge  metabolites,  and  oroidin  (1a,b)  is 
regarded as the parent compound for this type of compounds. We recently reported the antiprotozoal 
activity  of  oroidin  base  (1a),  oroidin  TFA  salt  (1b),  as  well  as  the  structurally  simpler  
4,5-dibromopyrrole-2-carboxylic  acid  and  3-amino-1-(2-aminoimidazoyl)-prop-1-ene,  all  obtained 
from a Turkish Agelas oroides specimen [7]. In addition, both oroidin forms were found to inhibit a 
key enzyme, PfFabI (enoyl-ACP reductase), of the plasmodial type II fatty acid biosynthesis pathway 
(PfFAS-II) [7]. The de novo PfFAS-II pathway, which was identified in P. falciparum in 1998 [8], was 
originally thought to be operated in the blood stage forms of the malaria parasite [9]. However, very 
recent studies suggest that the pathway is indispensible for the liver stage, which precedes the blood 
stage in humans, hence it is a very good target for malaria prophylaxis [10,11]. Stimulated by the data 
on oroidin, we decided to evaluate the antiprotozoal activity of  13 bromopyrrole alkaloids (2–14, 
Figure  1),  all  isolated  as free bases from Mediterranean marine sponges belonging to  Agelas and 
Axinella genera. The compounds were also tested against PfFabI as well as against two additional 
enzymes involved in PfFAS-II pathway of P. falciparum, PfFabG (β-ketoacyl-ACP reductase) and 
PfFabZ  (β-hydroxyacyl-ACP  dehydratase).  The  test  compounds  belong  to  different  subclasses, 
including oroidin analogs as hymenidin (2), dispacamide B (3), dispacamide D (4) , stevensine (5), and 
spongiacidin  B  (6),  and  their  derivatives  lacking  the  imidazole  ring,  such  as  bromoaldisin  (7), 
longamide B (8) and longamide A (9), and, finally, dimeric oroidin derivatives as sceptrin (10) and 
dibromopalau’amine  (11).  Three  non-oroidin  bromopyrrole  alkaloids  as  bromopyrrolohomoarginin 
(12), manzacidin A (13), and agelongine (14) have been also tested. To our knowledge this is the first 
study assessing the antiprotozoal activity of marine bromopyrrole alkaloids in detail. 
2. Results and Discussion 
The bromopyrrole alkaloids 2–14 were evaluated in vitro against the mammalian stages of four 
parasitic  protozoa:  Trypanosoma  brucei  rhodesiense  (bloodstream  forms),  T.  cruzi  (intracellular 
amastigotes in L6 rat skeletal myoblasts), Leishmania donovani (axenic amastigotes), and Plasmodium 
falciparum (erythrocytic stage of K1 strain, a chloroquine and pyrimethamine resistant strain). The Mar. Drugs 2010, 8                       
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toxicity on mammalian cells was assessed against L6 cells, a primary cell line derived from rat skeletal 
myoblasts. 
Figure 1. The chemical structures of bromopyrrole alkaloids 1–14. 
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Results compiled in Table 1 show that all compounds, except longamide A (9), displayed some 
activity against African trypanosome, T. brucei rhodesiense. The highest inhibition activity against this 
parasite was shown by dibromopalau’amine (11) (IC50 = 0.46 µ g/mL), followed by longamide B (8) Mar. Drugs 2010, 8                       
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(IC50  =  1.53  µ g/mL),  and  then  by  sceptrin  (10)  (IC50  =  9.71  µ g/mL)  and  spongiacidin  B  (6)  
(IC50 = 13.58 µ g/mL). The potency of the remaining alkaloids was moderate (25.35 to 77.64 µ g/mL). 
The activity against American trypanosome, T. cruzi, was much less pronounced or completely absent 
even at the highest test concentrations (90 µ g/mL). Interestingly, the compounds with the highest  
T. b. rhodesiense activity (dibromopalau’amine (11), longamide B (8), sceptrin (10), and spongiacidin 
B  (6))  plus  hymenidin  (2)  were  also  the  only  low  active  alkaloids  against  T.  cruzi  
(IC50 values > 33.03 µ g/mL). 
The majority of alkaloids also showed growth inhibition activity against Leishmania donovani and 
the most remarkable activity was shown by dibromopalau’amine (11) (IC50 value 1.09 µ g/mL) and 
longamide B (8) (IC50 = 3.85 µ g/mL). These activities are quite interesting since they fall almost in the 
same order of potency of the reference compound, miltefosine (IC50 = 0.21 µ g/mL). All the other 
alkaloids  were  much  less  active  than  11  and  8,  while  three  compounds,  dispacamide  B  (2), 
bromoaldisin (7), and longamide A (9), were completely inactive. 
Except for dispacamide D (4), bromoaldisin (7) longamide A (9) and manzacidin A (13), all the 
tested bromopyrrole alkaloids showed antiplasmodial activity against the multiple-drug resistant K1 
strain of P. falciparum. The most potent compounds were spongiacidin B (6) (IC50 = 1.09 µ g/mL), 
dispacamide B (3) (IC50 = 1.34 µg/mL) and dibromopalau’amine (11) (IC50 = 1.48 µ g/mL), all of them 
exhibiting a significant activity in the very low µ g/mL range. In comparison to the other parasites, the 
IC50 values of the remaining active alkaloids against P. falciparum were smaller (1.09–12.54 µ g/mL).  
When tested against mammalian (L6) cells (Table 1), only dibromopalau’amine (11) and longamide 
B (8) appeared to be associated with some toxicity (CC50 values of 4.46 and 9.94 µ g/mL, respectively). 
The selectivity index (SI, calculated by dividing the CC50 value against L6 cells to the IC50 value 
against the parasite) of dibromopalau’amine (11) for T. brucei rhodesiense was about 10. However, the 
SI values for L. donovani or P. falciparum were around 3–4, indicating a narrow therapeutic window. 
The CC50 values of longamide B (8) against mammalian cells were not much higher than its IC50 
values against T. brucei rhodesiense and L. donovani, again implying low selectivity indices (6.5 for  
T. brucei rhodesiense, and 2.6 against L. donovani). On the contrary, the CC50 value of spongiadicin B 
(6)  towards  L6  cells  is  about  30-times  higher  (CC50  =  35.6  µ g/mL)  than  that  against  
P. falciparum, while dispacamide B is devoid of any cytotoxicity at the highest test concentration  
(90  µ g/mL).  These  data unambiguously suggested that spongiacidin B (6) and dispacamide B (3) 
exhibited a selective antiplasmodial activity with IC50 values of 1.34 and 1.09 µ g/mL and SI values of 
32.7 and >67.2, respectively. 
Stimulated by data about the inhibitory activity of oroidin (1) against the P. falciparum PfFabI 
enzyme  [7],  we  evaluated  the  activity  of  all  the  bromopyrrole  alkaloids  2–14  against  three  key 
enzymes involved in the fatty acid pathway (FAS-II) of P. falciparum, namely PfFabI, PfFabG and 
PfFabZ. None of the test compounds showed activity (IC50 > 30 µ g/mL) against PfFabI and PfFabG, 
while a single compound, namely bromopyrrolohomoarginin (12), showed a very significant activity  
(IC50  =  0.28  µ g/mL)  against  PfFabZ.  Since  this  activity  is  identical  with  that  of  the  reference 
compound,  (-)-epigallocatechin  gallate  (IC50  =  0.32  µ g/mL),  it  is  surely  worthy  of  further 
investigation.  Mar. Drugs 2010, 8                       
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Table 1. In vitro antiprotozoal and cytotoxic activities of bromopyrroles 1–14. The IC50 
(protozoa) and CC50 (L6 cells) values are in μg/mL and represent the average of at least two 
independent assays performed in duplicates. 
Compound 
T. b. 
rhodesiense 
T. 
cruzi 
L. 
donovani 
P. 
falciparum 
Cytotoxicity 
L6 cells 
1a  17.30 
1  >30 
1  >30 
1  3.90 
1  88.60 
1 
1b  12.20 
1  >30 
1  15.40 
1  7.90 
1  76.40 
1 
2  77.64  73.10  29.87  12.54  75.73 
3  40.12  >90  >90  1.34  >90 
4  68.25  >90  53.75  >20  >90 
5  25.34  >90  75.86  4.88  >90 
6  13.48  72.25  41.59  1.09  35.61 
7   61.48  >90  >90  >20  >90 
8  1.53  33.03  3.85  7.46  9.94 
9  >90  >90  >90  >20  >90 
10  9.71  60.08  51.58  11.08  >90 
11  0.46  68.88  1.09  1.48  4.46 
12   67.13  >90  34.49  >20  62.32 
13  73.76  >90  75.83  >20  >90 
14  49.96  >90  43.22  11.18  >90 
Standards  0.004 
a  0.312 
b  0.206 
c  0.065 
d  0.005 
e 
Standard  compounds:
  a  Melarsoprol, 
b  Benznidazole, 
c  Miltefosine, 
d  Chloroquine, 
e  Podophyllotoxin.  
1 These results are from our earlier study [7]. 
Bromopyrrole alkaloids constitute a family of typically marine alkaloids and represent a fascinating 
example  of  the  chemical  diversity  of  secondary  metabolites  elaborated  by  marine  invertebrates. 
Indeed, about 160 members of this class have been isolated so far from more than 20 different sponges 
of  various  genera,  essentially  belonging  to  Agelasidae,  Axinellidae,  and  Halichondridae  families. 
Oroidin (1a,b) is considered the parent compound of this family and many bromopyrrole alkaloids 
possessing a  pyrrole-imidazole  structure can  be  conceived as  derivatives  of the C11N5 skeleton of 
oroidin. In a recent review [12], we have proposed the following classification of these alkaloids 
according  to  their  structures:  (a)  oroidin-like  linear  monomers;  (b)  polycyclic  oroidin  derivatives 
(including six different oroidin cyclization modes); (c) simple or rearranged oroidin-like dimers or 
higher oligomers; (d) non-oroidin bromopyrrole alkaloids. In the current study, all the above structural 
classes of bromopyrrole alkaloids were represented. Indeed, hymenidin (2), dispacamides B (3) and D 
(4) belong to the class of oroidin-like linear monomers; stevensine (5) and spongiacidin B (6) belong 
to the class of polycyclic oroidin derivatives; sceptrin (10) and dibromopalau’amine (11) are oroidin-
like dimers [13], while the six remaining alkaloids (7–9, 12–14) belong to the class of non-oroidin 
bromopyrroles, although some of them (7–9) appear to be strictly related to oroidin-like compounds, 
from which they differ for the lack of the imidazole ring. Manzacidin A (13) and agelongine (14) are 
characterized by an ester linkage in place of the amide linkage between the bromopyrrole unit and the 
remaining part of the molecule.  
The  interest  in  bromopyrrole  alkaloids  has  been  particularly  raised  by  the  number  of  different 
promising bio/pharmacological activities associated with them. Focusing on compounds evaluated in Mar. Drugs 2010, 8                       
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the present study: dispacamides (3,4) have been reported to possess a selective anti-histamine activity 
[14,15];  hymenidin  (2)  [16]  and  agelongine  (14)  [17]  were  reported  as  anti-serotonergic  agents; 
dibrompalau’amine (11) showed immunosuppressive properties [18]; sceptrin (10) proved to be an 
antibacterial and antifungal agent [19]. A very recent study reports on its inhibitory activity on the cell 
motility of several cancer cell lines, without cytotoxicity, with potential application in human diseases 
as cancer and chronic inflammation [20].  
In the present study, a reasonable number of bromopyrrole alkaloids have been tested for growth 
inhibitory activity against a panel of parasitic protozoa. In the first glance, the detected antiprotozoal 
activities do not appear to be associated to a specific structural class. For example, a good inhibitory 
activity against Trypanosoma brucei rhodesiense and Leishmania donovani has been shown by an 
oroidin dimer (dibromopalau’amine) (11) and by a non-oroidin alkaloid (longamide B) (8). However, 
there are some conclusions to be drawn for the growth inhibitory activities of the metabolites towards 
these two parasites. Oroidin (1a) or its TFA salt (1b), which contain two bromine atoms on the pyrrole 
ring  are  more  active  [7]  than  the  related  monobromo  compounds  2–4.  This  might  indicate  the 
importance of two Br atoms on adjacent pyrrole carbons for activity against T. brucei rhodiense and 
Leishmania.  The  most  active  trypanocidal  and  leishmanicidal  compounds  are  an  oroidin  dimer 
(dibromopalau’amine (11) and a non-oroidin alkaloid (longamide B) (8). The existence of two bromine 
groups in 11 might have some impact on its bioactivity. The second most active compound longamide 
B (8) differs from the inactive longamide A (9), which was completely inactive against any protozoan 
parasite,  by  the  presence  of  a  carboxymethyl  function.  It  appears  that  this  group  might  also  be 
responsible for the cytotoxicity of 8, since 9 is also non-toxic.  
The best antimalarial activity has been exhibited by a linear oroidin-like compound (dispacamide B) 
(3),  by  a  polycyclic  oroidin  derivative  (spongiacidin  B)  (6),  and  by  an  oroidin  dimer 
(dibromopalau’amine) (11). The structural similarity within the series of molecules tested in this study 
allows the formulation of some preliminary structure-activity relationships also for the antimalarial 
activity. The two most potent antimalarial alkaloids, dispacamide B (3) and spongiacidin B (6) show 
an  oroidin-like  structure  with  oxidation  of  the  aminoimidazole  to  aminoimidazolone  (alkylidene 
glycocyamidine) ring. The clear positive impact of this structural feature becomes even more obvious 
when these compounds are compared with closely related analogs. The much less active hymenidin (2) 
differs from dispacamide B (3) just by the oxidation of the aminoimidazole ring. The same relationship 
connects spongiacidin B (6) and stevensine (5), which is almost five-times less active than the former. 
Moreover, when compared with oroidin, both compounds 3 and 6 appear to display better antimalarial 
potency (Table 1). The low activity of dispacamide D (4) indicates that the presence of an hydroxyl 
group within the linear alkyl chain is unfavorable for the antimalarial activity. The comparison of 
antimalarial potencies of spongiacidin B (6) and bromoaldisin (7) clearly indicates that the imidazole-
type ring must play a pivotal role for the antimalarial activity. 
The malaria parasite undergoes two life stages in the human body, a liver stage, followed by short 
cycles  of  the  erythrocytic  (blood)  stage.  Lately,  the  liver  phase  of  the  infection  is  gaining  more 
attention as its inhibition provides a causal prophylaxis, i.e., prevents the blood stage infection and the 
clinical symptoms of the disease. It has been recently demonstrated that liver stage malaria parasites 
exhibit an absolute requirement for de novo FAS-II pathway. The deletion or inhibition of critical 
elongation enzymes such as FabI or FabZ enzymes results in the inability to cause a erythrocytic Mar. Drugs 2010, 8                       
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infection, hence death of the parasite [10,11]. Thus, FAS-II pathway has become an ideal target for 
malaria prophylaxis. 
In  a  previous  project,  we  identified  both  oroidin  base  (1a)  and  its  salt  (1b)  as  potent  PfFAbI 
inhibitors [7]. In the current study, none of the compounds inhibited the PfFabI (enoyl-ACP reductase) 
enzyme. This again might indicate the importance of two o-positioned bromine atoms in oroidin-like 
compounds for PfFabI inhibitory activity. However, several compounds contain such functionality in 
their structures, suggesting that structural requirements to inhibit the PfFabI enzyme are likely to be 
more  complex.  Notably,  only  bromopyrrolohomoarginin  (12),  showed  a  very  significant  activity 
against another crucial PfFAS-II enzyme PfFabZ. Due to its inhibitory activity against this enzyme, 
compound 12 might have potential in malaria prophylaxis.  
3. Experimental Section  
3.1. Isolation of compounds 2–14 
Compounds 2–14 were isolated as free bases from different sponges belonging to the genera Agelas 
and Axinella, using different chromatographic techniques, as described previously, and characterized 
by means of spectroscopic techniques. Sceptrin (10), hymenidin (2), dispacamides B (3) and D (4) 
have been obtained from four different Agelas sponges (A. conifera, A. clathrodes, A. longissima, A. 
dispar)  [14,15].  Stevensine  (5),  spongiacidin  B  (6),  bromoaldisin  (7),  dibromopalau’amine  (11), 
compound 12 and manzacidin A (13) have been obtained from Axinella verrucosa [21]. Longamide A 
(9) has been obtained from Agelas longissima [22], longamide B (8) has been obtained from Agelas 
dispar [23]. Agelongine (14) was initially obtained from Agelas longissima [17], however, it has been 
later found as component of the polar fractions of practically all the  Agelas and Axinella species 
investigated in our laboratory so far. The purity of all these compounds (>95%) was confirmed by  
1H- and 
13C-NMR.  
3.2. Activity against Plasmodium falciparum  
In  vitro  activity  against  erythrocytic  stages  of  P.  falciparum  was  determined  by  a  modified  
[
3H]-hypoxanthine incorporation assay [24] using the chloroquine- and pyrimethamine-resistant K1 
strain and the standard drug chloroquine. Briefly, parasite cultures incubated in RPMI 1640 medium 
with 5% Albumax (without hypoxanthine) were exposed to serial drug dilutions in microtiter plates. 
After 48 h of incubation at 37 ° C in a reduced oxygen atmosphere, 0.5 Ci 
3H-hypoxanthine was 
added  to  each  well.  Cultures  were  incubated  for  a  further  24  h  before  they  were  harvested  onto  
glass-fiber filters and washed with distilled water. The radioactivity was counted using a Betaplate
TM 
liquid scintillation counter (Wallac, Zurich, Switzerland). The results were recorded as counts per 
minute  (CPM)  per  well  at  each  drug  concentration  and  expressed  as  percentage  of  the  untreated 
controls. IC50 values were calculated from graphically plotted dose-response curves. Each IC50 value 
obtained is the mean of at least two separate experiments performed in duplicate  (the variation is 
maximum 20%). Mar. Drugs 2010, 8                       
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3.3. Activity against Trypanosoma brucei rhodesiense  
STIB 900 strain of T. b. rhodesiense and the standard drug melarsoprol were used for the assay 
[25].  Minimum  Essential  Medium  (50  μL)  supplemented  with  25  mM  HEPES,  1g/L  additional 
glucose, 1% MEM non-essential amino acids (100× ), 0.2 mM 2-mercaptoethanol, 1mM Na-pyruvate 
and 15% heat inactivated horse serum was added to each well of a 96-well microtiter plate [26]. Serial 
drug dilutions of seven 3-fold dilution steps covering a range from 90 to 0.123 μg/mL were prepared. 
Then 10
4 bloodstream forms of T. b. rhodesiense STIB 900 in 50 μL was added to each well and the 
plate incubated at 37 ° C under a 5 % CO2 atmosphere for 72 h. 10 µL  of a resazurin solution (12.5 mg 
resazurin dissolved in 100 mL double-distilled water) was then added to each well and incubation 
continued for a further 2–4 h. Then the plates were read in a Spectramax Gemini XS microplate 
fluorometer (Molecular Devices Cooperation, Sunnyvale, CA, USA) using an excitation wavelength of 
536 nm and an emission wavelength of 588 nm. Data were analyzed using the microplate reader 
software  Softmax  Pro  (Molecular  Devices  Cooperation,  Sunnyvale,  CA,  USA).  Each  IC50  value 
obtained is the mean of at least two separate experiments performed in duplicate  (the variation is 
maximum 20%). 
3.4. Activity against Trypanosoma cruzi 
Rat skeletal myoblasts (L6 cells) were seeded in 96-well microtitre plates at 2000 cells/well in  
100 μL  RPMI  1640  medium  with  10%  FBS  and  2  mM  l-glutamine. After  24 h the medium was 
removed and replaced by 100 μl per well containing 5000 trypomastigote forms of T. cruzi Tulahuen 
strain C2C4 containing the β-galactosidase (Lac Z) gene [27]. After 48 h, the medium was removed 
from the wells and replaced by 100 μl fresh medium with or without a serial drug dilution of seven  
3-fold dilution steps covering a range from 90 to 0.123 μg/mL. After 96 h of incubation the plates were 
inspected  under  an  inverted  microscope  to  assure  growth  of  the  controls  and  sterility.  Then  the 
substrate CPRG/Nonidet (50 μl) was added to all wells. A color reaction developed within 2–6 h and 
could be read photometrically at 540 nm. Data were transferred into the graphic programme Softmax 
Pro (Molecular Devices), which calculated IC50 values. Each IC50 value obtained is the mean of at 
least two separate experiments performed in duplicate (the variation is max. 20%). Benznidazole was 
the standard drug used. 
3.5. Activity against Leishmania donovani 
Amastigotes of L. donovani strain MHOM/ET/67/L82 were grown in axenic culture at 37 ° C in SM 
medium at pH 5.4 supplemented with 10% heat-inactivated fetal bovine serum under an atmosphere of 
5% CO2 in air. One hundred μL of culture medium with 10
5 amastigotes from axenic culture with or 
without a serial drug dilution were seeded in 96-well microtiter plates. Serial drug dilutions covering a 
range from 90 to 0.123 μg/mL were prepared. After 72 h of incubation the plates were inspected under 
an inverted microscope to assure growth of the controls and sterile conditions. 10 µL of a resazurin 
solution (12.5 mg resazurin dissolved in 100 mL double-distilled water) [28] was then added to each 
well and the plates incubated for another 2 h. Then the plates were read in a Spectramax Gemini XS 
microplate fluorometer using an excitation wavelength of 536 nm and an emission wavelength of  Mar. Drugs 2010, 8                       
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588 nm. Data were analyzed using the software Softmax Pro. Decrease of fluorescence (=inhibition) 
was  expressed  as  percentage  of  the  fluorescence  of  control  cultures  and  plotted  against  the  drug 
concentrations. From the sigmoidal inhibition curves the IC50 values were calculated. Each IC50 value 
obtained is the mean of at least two separate experiments performed in duplicate (the variation is max. 
20%). Miltefosine was used as a reference drug. 
3.6. Cytotoxicity against L6-cells 
Assays were performed in 96-well microtiter plates, each well containing 100 μL of RPMI 1640 
medium supplemented with 1% L-glutamine (200 mM) and 10% fetal bovine serum, and 4 ×  10
4 L-6 
cells (a primary cell line derived from rat skeletal myoblasts). Serial drug dilutions of seven 3-fold 
dilution steps covering a range from 90 to 0.123 μg/mL were prepared. After 72 h of incubation the 
plates  were  inspected  under  an  inverted  microscope  to  assure  growth  of  the  controls  and  sterile 
conditions. 10 μl of a resazurin solution (12.5 mg resazurin dissolved in 100 mL distilled water) was 
then added to each well and the plates incubated for another 2 h. Then the plates were read with a 
Spectramax Gemini XS microplate fluorometer using an excitation wavelength of 536 nm and an 
emission wavelength of 588 nm. Data were analyzed using the microplate reader software Softmax 
Pro. Each CC50 value obtained is the mean of at least two separate experiments performed in duplicate. 
Podophyllotoxin was the standard drug used. 
3.7. PfFAS-II enzyme inhibition assays 
Expression  and  purification  of  the  PfFab  enzymes  as  well  as  the  assays  were  performed  as 
described [29]. The enzyme inhibition was monitored using a Perkin Elmer Envision 2101 Multilabel 
Reader. Measurements were carried out in Nundron Surface sterile 96-well plates, using 20 mM Hepes 
and 150 mM NaCl at pH 7.4. Compounds were dissolved in DMSO (maximum final concentration 
1%). A dilution series of 50 μg/mL to 0.0005 μg/mL of dissolved compounds was measured. For 
PfFabI, 400 μM NADH (cofactor, Sigma) was added to 2 µg enzyme and reaction started by addition 
of 300 μM crotonyl-CoA (substrate, Sigma). The change of absorbance of the mixture was recorded 
spectrophotometrically at 340 nm for 40 minutes. Triclosan was used as a positive control and was 
analyzed the same way. For PfFabG 400 μM NADPH (cofactor, Fluka) was added to 0.5 µg enzyme 
and  reaction  started  by  addition  of  300  μM  acetoacetyl-CoA  (substrate,  Sigma).  The  change  of 
absorbance  of  the  mixture  was  recorded  spectrophotometrically  at  340  nm  for  20  minutes.  
(-)-Epigallocatechin gallate (Sigma) was used as a positive control and was analyzed the same way. 
For PfFabZ, 600 μM crotonoyl-CoA (substrate, Sigma) was added to 0.5 µ g enzyme. The change of 
absorbance  of  the  mixture  was  recorded  spectrophotometrically  at  260  nm  for  20  minutes.  
(-)-Epigallocatechin  gallate  was  used  as  a  positive  control.  IC50  values  were  estimated  from 
graphically plotted dose-response curves. Each IC50 value obtained is the mean of at least two separate 
experiments performed in duplicate. Mar. Drugs 2010, 8                       
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4. Conclusions  
The  present  study  constitutes  the  first  report  on  the  wide-spectrum  antiprotozoal  activity  of 
bromopyrrole alkaloids, one of the best known and chemically diverse classes of marine alkaloids. We 
have  identified  dispacamide  B  (3)  and  spongiacidin  B  (6)  as  antimalarial  lead  compounds,  with 
significant  activity  and  low  or  no  toxicity  towards  mammalian  cells.  Our  data  indicated  that 
dibromopalau’amine (11) and longamide B (8) are potent trypanocidal and antileishmanial agents, 
with narrower therapeutic windows. These lead compounds could be converted to more selective and 
more  potent  trypanocidal  antiprotozoal  drugs  by  medicinal  chemistry  approach.  The  preliminary 
structure-activity relationships deduced should encourage further studies aimed at investigating their 
mechanisms of action as well as at optimizing their antiprotozoal activities. The availability of tens of 
other natural bromopyrroles and the possibility of obtaining some non-natural derivatives through total 
synthesis (model total syntheses for dispacamide B [30] and longamide B [31] have been reported) 
could be particularly helpful to this aim. 
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